Pancreatic Cancer Research

ResearcherSapporo Medical UniversityActive in the last 2 years

Daisuke Kyuno

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4672-535X; OpenAlex author ID A5008145283. Sources: OpenAlex.

Their work

Papers
13 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
19
Papers, trials and grants by year

2011: 3 papers · 2012: 1 paper · 2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 2 papers · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 13

  1. Concordance of claudin-18.2 expression in biopsy, resection, and recurrent specimens: implications for zolbetuximab therapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/21688370.2025.2535047↗
  2. The Role of Claudin-1 in Enhancing Pancreatic Cancer Aggressiveness and Drug Resistance via Metabolic Pathway Modulation. Co-author DOI 10.3390/cancers17091469↗
  3. Role of preoperative circulating tumor DNA in predicting occult metastases in resectable and borderline resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.3748/wjg.v31.i32.109383↗
  4. Perioperative Predictors of Early Recurrence for Resectable and Borderline-Resectable Pancreatic Cancer. Co-author DOI 10.3390/cancers13102285↗
  5. Tricellular tight junction protein LSR/angulin-1 contributes to the epithelial barrier and malignancy in human pancreatic cancer cell line. First author DOI 10.1007/s00418-019-01821-4↗
  6. Glucose-Dependent FOXM1 Promotes Epithelial-to-Mesenchymal Transition Via Cellular Metabolism and Targeting Snail in Human Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001485↗
  7. Claudin-4 binder C-CPE 194 enhances effects of anticancer agents on pancreatic cancer cell lines via a MAPK pathway. Co-author DOI 10.1002/prp2.196↗
  8. Targeting tight junctions during epithelial to mesenchymal transition in human pancreatic cancer. Co-author DOI 10.3748/wjg.v20.i31.10813↗
  9. Protein kinase Cα inhibitor protects against downregulation of claudin-1 during epithelial-mesenchymal transition of pancreatic cancer. Co-author DOI 10.1093/carcin/bgt057↗
  10. Targeting claudin-4 in human pancreatic cancer. First author DOI 10.1517/14728222.2012.708340↗
  11. Transcriptional regulation of claudin-18 via specific protein kinase C signaling pathways and modification of DNA methylation in human pancreatic cancer cells. Co-author DOI 10.1002/jcb.23095↗
  12. Protein kinase Cα inhibitor enhances the sensitivity of human pancreatic cancer HPAC cells to Clostridium perfringens enterotoxin via claudin-4. Co-author DOI 10.1007/s00441-011-1287-2↗
  13. Downregulation of tight junction-associated MARVEL protein marvelD3 during epithelial-mesenchymal transition in human pancreatic cancer cells. Co-author DOI 10.1016/j.yexcr.2011.06.020↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masafumi Imamura · 9 shared papers, 2011–2026 · strength 1.21
  2. Yasutoshi Kimura · 8 shared papers, 2011–2025 · strength 0.87
  3. Takashi Kojima · 9 shared papers, 2011–2025 · strength 0.64
  4. Makoto Osanai · 2 shared papers, 2025–2026 · strength 0.56
  5. Ichiro Takemasa · 4 shared papers, 2020–2025 · strength 0.55
  6. Tatsuya Ito · 6 shared papers, 2011–2026 · strength 0.49
  7. Takumi Konno · 4 shared papers, 2015–2025 · strength 0.48
  8. Akira Takasawa · 5 shared papers, 2011–2025 · strength 0.33
  9. Takuro Kyuno · 2 shared papers, 2020 · strength 0.22
  10. Norimasa Sawada · 6 shared papers, 2011–2015 · strength 0.21
  11. Makoto Yoshida · 1 shared paper, 2025 · strength 0.20
  12. Tomohiro Kubo · 1 shared paper, 2025 · strength 0.20
  13. Tõru Nakamura · 1 shared paper, 2025 · strength 0.20
  14. Siew‐Kee Low · 1 shared paper, 2025 · strength 0.20
  15. Kazunori Watanabe · 1 shared paper, 2025 · strength 0.20
  16. Takeshi Murakami · 1 shared paper, 2025 · strength 0.20
  17. Masayo Motoya · 1 shared paper, 2025 · strength 0.20
  18. Koichi Hirata · 5 shared papers, 2011–2015 · strength 0.15
  19. Tsuyoshi Kono · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.